Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 5/2017 | Aadi | Series A | 23M |
| 12/2022 | Pulmocide | Series C | 0 |
| 5/2004 | CAPNIA | Series B | 12M |
| 11/2022 | Bonum | Series A | 93M |
| 2/2019 | Bolt | Series B | 54M |
| 9/2021 | INBRACE | Series D | 0 |
| 11/2004 | ViOptix | Series C | 0 |
| 5/2015 | REGENXBIO | Series D | 0 |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 10/2020 | Olema Oncology | Series C | 85M |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2019 | INBRACE | Series C | 45M |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 3/2021 | OMNI | Series D | - |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 8/2022 | Klavi | Series A | 15M |
| 12/2020 | dMed | Series C | 100M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 12/2020 | Provivi | Series C | 0 |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 9/2014 | AirXpanders | Series E | 1M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 3/2023 | EpiBiologics | Series A | 0 |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 7/2015 | Gengmei | Series B | - |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 11/2017 | OMNI | Series C | - |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 12/2022 | Ronovo Surgical | Series B | - |
| 8/2008 | InteKrin | Series C | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 11/2019 | Genetron Health | Series D | 71M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 1/2007 | InteKrin | Series B | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 7/2016 | Tricida | Series C | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 6/2013 | AirXpanders | Series E | 9M |
| 6/2012 | SentreHEART | Series C | 26M |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 11/2017 | Tricida | Series D | 0 |
| 9/2021 | Attralus | Series B | 116M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 1/2010 | Neomend | Series D | 30M |
| 6/2009 | Sagent | Series A | 30M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 10/2003 | Cotherix | Series C | 55M |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 4/2021 | Ronovo Surgical | Series A | - |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 1/2021 | IO Biotech | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 3/2019 | MacuLogix | Series D | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 3/2021 | Ossium Health | Series B | 63M |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 9/2016 | ReadCoor | Series A | 23M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
